<DOC>
	<DOCNO>NCT02007473</DOCNO>
	<brief_summary>The objective non-interventional study gather data adverse reaction occur Methylene Blue plasma administer routine clinical practice environment ; know characteristic behaviour possible factor may influence presentation evolution .</brief_summary>
	<brief_title>A Prospective Non-interventional Study Evaluate Safety Methylene Blue Plasma</brief_title>
	<detailed_description>This open label , multi-centre , non-controlled , non-randomized , non-interventional study evaluate safety Methylene Blue ( MB ) plasma . One centre per country participate United Kingdom , Belgium , Greece Spain . The haemovigilance Case Report Form ( CRF ) complete patient receive Methylene Blue plasma transfusion experience adverse reaction . The patient monitor occurrence possible adverse reaction within 24 hour start transfusion . If patient experience adverse reaction , information adverse reaction document . Serious adverse reaction collect within 7-day period transfusion . Each adverse reaction serious adverse reaction follow 28 day occurrence reaction . Each centre provide number transfuse Methylene Blue plasma unit number transfuse Methylene Blue plasma patient every three month . Information collect haemovigilance CRF include : - Details transfusion ( transfused unit , volume , non-plasma blood component transfuse ) - Details plasma ( collected whole blood , aphaeresis , filter use , type reference use , illumination device model ) - Demographic data - Transfusion history ( include hospital department ) - History previous transfusion reaction - Details adverse reaction ( date time reaction ) - Signs symptom allocation diagnosis - Classification adverse reaction ( severity , imputability , non-serious serious ) - Actions take - Outcome - Time recovery</detailed_description>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>Patients , receive transfusion Methylene Blue plasma produce use THERAFLEX MBPlasma procedure MacoPharma experience adverse reaction . Patients receive transfusion plasma type transfusion episode</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Haemovigilance</keyword>
	<keyword>Plasma</keyword>
	<keyword>Pathogen reduction</keyword>
	<keyword>Methylene Blue</keyword>
</DOC>